Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
作者信息
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
出版信息
Oncologist. 2021 Mar;26(3):e522. doi: 10.1002/onco.13691.
Abstract
摘要
相似文献
1
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist. 2021 Mar;26(3):e522. doi: 10.1002/onco.13691.
2
Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.
Cancer Manag Res. 2022 Mar 19;14:1179-1194. doi: 10.2147/CMAR.S348591. eCollection 2022.
3
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.
4
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
5
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Ann Pharmacother. 2019 Feb;53(2):178-185. doi: 10.1177/1060028018795146. Epub 2018 Aug 13.
6
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.
NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.
7
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
J Oncol Pharm Pract. 2020 Sep;26(6):1486-1491. doi: 10.1177/1078155220934531. Epub 2020 Jun 23.
8
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Curr Med Res Opin. 2017 Sep;33(9):1559-1569. doi: 10.1080/03007995.2017.1348344. Epub 2017 Jul 25.
9
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
J Oncol Pharm Pract. 2019 Jan;25(1):110-129. doi: 10.1177/1078155218770904. Epub 2018 May 4.
10
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.
引用本文的文献
1
Abemaciclib-Associated Panniculitis With Fibrosis: Expanding the Dermatologic Spectrum of Cyclin-Dependent Kinase 4/6 Inhibitors.
Cureus. 2025 May 2;17(5):e83380. doi: 10.7759/cureus.83380. eCollection 2025 May.
2
Local Control of Advanced Breast Cancer-Debate in Multidisciplinary Tumor Board.
J Clin Med. 2025 Jan 15;14(2):510. doi: 10.3390/jcm14020510.
3
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.
Breast. 2025 Feb;79:103875. doi: 10.1016/j.breast.2025.103875. Epub 2025 Jan 10.
4
Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors.
Genome Biol. 2024 Dec 2;25(1):301. doi: 10.1186/s13059-024-03438-w.
5
Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer.
Curr Oncol. 2024 Sep 12;31(9):5374-5383. doi: 10.3390/curroncol31090397.
6
Challenges of Renal Function Assessment in Breast Cancer Patients Treated With Abemaciclib: A Case Report.
Cureus. 2024 Aug 25;16(8):e67714. doi: 10.7759/cureus.67714. eCollection 2024 Aug.
7
Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
CNS Neurosci Ther. 2024 Jul;30(7):e14862. doi: 10.1111/cns.14862.
8
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Clin Cancer Res. 2024 Jun 3;30(11):2377-2383. doi: 10.1158/1078-0432.CCR-23-3436.
9
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients.
Oncologist. 2024 Apr 4;29(4):e455-e466. doi: 10.1093/oncolo/oyad304.
10
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):1955-1962. doi: 10.31557/APJCP.2023.24.6.1955.
Zotero 插件